P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
A legfontosabb adatok
- Ki végzi
- Poseida Therapeutics, Inc.
- Hol
- Baltimore, Boston, Denver, Duarte, Nashville, New Orleans, New York, San Diego és San Francisco (Egyesült Államok)Mind a 10 helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1. fázis
- Résztvevők
- 40 fő vett részt
- Kezdés
- 2020. febr. 28.
- Befejezés
- 2024. szept. 30.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoport
- A vizsgált kezelések
- P-PSMA-101 CAR-T cells
- Rimiducid
- A regiszteradat frissítve
- 2025. február 17.
- Miért állt le
- Study closed
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Subjects ≥18 years of age
- Must have a confirmed diagnosis of mCRPC or SGC
- Must have measurable disease by RECIST 1.1 or bone only metastases with measurable PSA (≥1 ng/mL) (mCRPC subjects only)
- Must have progressed by PCWG3 and/or RECIST 1.1 (mCRPC subjects only)
- Must be willing to practice birth control from screening and for 2 years after the last administration of P-PSMA-101
- Must have adequate vital organ function within pre-determined parameters
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Ki nem vehet részt
- Has received anti-cancer medications (excluding GnRH targeted therapies) within 2 weeks of the time of initiating conditioning chemotherapy
- Has received immunosuppressive medications (including anti-cancer medications) within 2 weeks of initiating leukapheresis and/or expected to require them while enrolled in the study
- Has received systemic corticosteroid therapy within 2 weeks of either the required leukapheresis or is expected to require it during the course of the study
- Has an active second malignancy in addition to mCRPC or SGC, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
- Has a history of or active autoimmune disease
- Has a history of significant central nervous system (CNS) disease, such as stroke or epilepsy
- Has an active systemic (viral, bacterial or fungal) infection
- Has a history of significant ocular disease
- Has a history of significant liver disease or active liver disease
- Has a history of or known predisposition to HLH or MAS
- Has inadequate venous access and/or contraindications to leukapheresis
- Has CNS metastases or symptomatic CNS involvement
- Has liver metastases (<5 lesions and maximum diameter </= 2.5 cm permitted)
Helyszínek itt: Egyesült Államok
- University of Maryland, BaltimoreBaltimore, Egyesült Államok
- Dana-Farber Cancer InstituteBoston, Egyesült Államok
- Massachusetts General HospitalBoston, Egyesült Államok
- Sarah Cannon Research Institute at HealthONEDenver, Egyesült Államok
- City of Hope Comprehensive Cancer CenterDuarte, Egyesült Államok
- Tennessee OncologyNashville, Egyesült Államok
- Tulane University Hospital and ClinicNew Orleans, Egyesült Államok
- Memorial Sloan-Kettering Cancer CenterNew York, Egyesült Államok
- University of California San DiegoSan Diego, Egyesült Államok
- University of California San FranciscoSan Francisco, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
A vizsgálat 4 csoportja
- P-PSMA-101 CAR-T cells (Single Dose - Part 1a)A vizsgált kezelés
Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
Kezelés: P-PSMA-101 CAR-T cells és Rimiducid
- P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)A vizsgált kezelés
Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
Kezelés: P-PSMA-101 CAR-T cells és Rimiducid
- P-PSMA-101 CAR-T cells (Single Dose - Part 1c)A vizsgált kezelés
Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
Kezelés: P-PSMA-101 CAR-T cells és Rimiducid
- P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)A vizsgált kezelés
Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
Kezelés: P-PSMA-101 CAR-T cells és Rimiducid
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
- A regiszteradat frissítve
- 2025. február 17.